A well-known headline evokes a certain emotion. “New Covid variant detected.” The majority of people in Britain have by now become somewhat immune to the alarm itself, scrolling by, reading half of it, and moving on. It makes sense to have that reflex. Additionally, experts are starting to subtly speculate as to why this specific moment merits more attention.
The variant, known as BA.3.2, has been given the nickname “Cicada” in honor of the insect that goes underground for years before emerging in enormous, noisy numbers. T. Ryan Gregory, an evolutionary biologist at the University of Guelph who has been tracking Covid variants informally since the beginning of Omicron, came up with the name in December 2025. There is more to the comparison than just poetry. In November 2024, this strain was discovered in a five-year-old boy in South Africa before appearing to disappear. By September 2025, it was spreading throughout Northern Europe after infiltrating Mozambique, the Netherlands, and Germany. The UK Health Security Agency is currently keeping a close eye on its spread after it was confirmed there.
| Key Facts: BA.3.2 “Cicada” Variant | |
|---|---|
| Official Name | BA.3.2 (SARS-CoV-2 subvariant) |
| Nickname | Cicada |
| First Detected | November 22, 2024 – South Africa |
| First UK Detection | Confirmed; monitored by UK Health Security Agency (UKHSA) |
| Countries Affected | At least 23 countries as of February 2026 |
| WHO Classification | Variant Under Monitoring (VUM) — lowest monitoring tier |
| Spike Protein Mutations | Approximately 70–75 changes |
| Lineage | Descendant of Omicron subvariant BA.3 |
| Severity | No evidence of increased severity vs. prior variants |
| Vaccine Impact | Current JN.1-targeted vaccines may be less effective against infection; still offer protection against severe disease |
| Key Symptoms | Sore throat, cough, fatigue, headache, fever, congestion; some cases report nausea or diarrhoea |
| UK Expert Leading Analysis | Prof. Ravi Gupta, Cambridge University |
| Reference / Further Reading | CDC BA.3.2 Surveillance Report |
The sheer weight of Cicada’s mutations sets it apart from the long line of Greek-lettered and colloquially named variations that have preceded it. The spike protein, which is the portion of the virus that adheres to human cells and, importantly, the portion that vaccines are intended to assist the immune system in recognizing, has between 70 and 75 alterations in BA.3.2. In contrast, current vaccines are based on strains of the JN.1 lineage, which have dominated circulation in the US and the UK since early 2024. In terms of genetics, Cicada is practically alien.
Prof. Ravi Gupta of Cambridge University, who served on the New and Emerging Respiratory Virus Threats Advisory Group and provided advice to the UK government during the pandemic’s peak, has been straightforward about what that entails. “This is different from the viruses we have been dealing with for the last two years,” he said this week to the Mirror. He anticipates that Cicada will overtake all other strains in the UK. In the lab, he is already witnessing it. He and his colleagues are currently looking closely at a signal that suggests the variant may be spreading disproportionately among children, though it is still early and unconfirmed. The main theory is fairly simple: a large number of young children have never received a Covid-19 vaccination, so their immune systems have no prior framework for identifying the virus. According to Prof. Gupta, they are “in the front line.”
It’s important to be clear about what that means and doesn’t. As of right now, there is no proof that Cicada causes more serious illness than its predecessors. Hospitalization rates have not substantially increased above normal seasonal patterns in Germany, Denmark, and the Netherlands, where the variant has already reached about 30% of sequenced Covid cases. BA.3.2 is categorized by the World Health Organization as a “Variant Under Monitoring,” which is the lowest monitoring tier. This is not a declaration of emergency. Nonetheless, it is a sign that surveillance is increasing and that scientists are uncomfortable with the idea that nothing will change.
What happens at the population level when a fast-spreading variant encounters an immune landscape that it can partially avoid is the more urgent concern. More infections result from even a slight decline in vaccine efficacy. People who are elderly, immunocompromised, or suffering from chronic illness eventually contract more infections, even minor ones. The fact that Prof. Gupta reported seeing three Covid patients in a single week last week serves as a reminder that the virus has not gone away, despite the fact that public discourse about it has mostly stopped. “The immunocompromised and the elderly are at the biggest risk,” he stated, “but vaccines should prevent some of the most severe complications in most people.”
The prevailing scientific explanation for Cicada’s existence at all with so many mutations in a single strain is what has been referred to as a “patient zero” scenario. According to the theory put forth by Prof. Gupta and others, BA.3.2 replicated for a considerable amount of time—possibly over a year—inside a single person whose immune system was seriously weakened, possibly as a result of HIV or immunosuppressive cancer treatment. The virus was able to accumulate mutations in that one host at a rate that would not be possible in an immune system that was operating normally. It was something truly novel when it finally made its way into widespread use.
For their part, the symptoms are well-known: fever, headache, exhaustion, congestion, sore throat, and cough. Although it is not always the case, some CDC-tracked cases have also reported gastrointestinal problems, such as nausea or diarrhea. There isn’t a single “Cicada symptom” that clearly sets it apart from other respiratory infections. This contributes to the difficulty of tracking it, particularly since formal testing has drastically decreased since the pandemic’s peak years.
JN is the target of the current Covid vaccines.1 lineage strains are probably less successful in preventing Cicada infection. Reduced recognition of antibodies is suggested by lab studies. However, the majority of scientists agree that vaccination still provides significant protection against serious illness and hospitalization, and that getting vaccinated is still beneficial, especially for vulnerable populations. It is noteworthy that antiviral medications such as Paxlovid seem to continue to be effective against BA.3.2.
Whether Cicada will cause a significant summer wave in the UK is still up in the air. Since 2020, waves have appeared in every month of the year, and Covid does not track seasons with the consistency of influenza. Based on everything seen in the lab and in wastewater surveillance systems, it appears more and more likely that this variant is not going extinct. It’s here, it’s spreading, and it’s doing so in a population that might not be as vigilant as it once was after five years of variations.
The way Cicada acts in the upcoming weeks will determine whether or not that complacency matters. The scientists most directly involved seem to know more than they are prepared to state with certainty as they watch this develop. Public health decisions become challenging when there is a gap between suspicion and confirmation, leaving the rest of us to read the headlines once more and question how seriously to take them this time.
